25 April 2023
Kirkland Represents Eli Lilly on Divesture of BAQSIMI to Amphastar
Advising firms
Deal team
14 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Michael Brueck Lead | Kirkland & Ellis | Partner | corporate | Not stated |
| Steven Li Lead | Kirkland & Ellis | Partner | corporate | Not stated |
| Alexandra Gallogly | Kirkland & Ellis | Associate | corporate | Not stated |
| Justin Prindle | Kirkland & Ellis | Associate | corporate | Not stated |
| Ben Howard | Kirkland & Ellis | Associate | corporate | Not stated |
| Amber Harezlak | Kirkland & Ellis | Partner | technology & intellectual property | Not stated |
| Trevor Snider | Kirkland & Ellis | Associate | technology & intellectual property | Not stated |
| Min Ryoo | Kirkland & Ellis | Associate | technology & intellectual property | Not stated |
| Andrea Murino | Kirkland & Ellis | Partner | antitrust & competition | Not stated |
| Samantha Morelli | Kirkland & Ellis | Partner | antitrust & competition | Not stated |
| Dean Shulman | Kirkland & Ellis | Partner | tax | Not stated |
| Adam Kool | Kirkland & Ellis | Partner | tax | Not stated |
| Sharon Freiman | Kirkland & Ellis | Partner | capital markets | Not stated |
| Ashley Gregory | Kirkland & Ellis | Partner | debt finance | Not stated |
Stated terms
- Stated value
- USD 1.07bn ($1.075 billion)
- What the figure measures
- Total transaction value
- Client
- Eli Lilly and CompanySell-side
- Counterparties
- Amphastar Pharmaceuticals, Inc. (Buy-side)